SK bioscienceLtd Future Growth
Future criteria checks 0/6
SK bioscienceLtd's revenue and earnings are forecast to decline at 3.5% and 9.4% per annum respectively. EPS is expected to decline by 9% per annum. Return on equity is forecast to be -1.4% in 3 years.
Key information
-9.4%
Earnings growth rate
-9.0%
EPS growth rate
Biotechs earnings growth | 52.5% |
Revenue growth rate | -3.5% |
Future return on equity | -1.4% |
Analyst coverage | Good |
Last updated | 29 Jun 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 316,492 | 24,953 | -5,000 | 15,000 | 4 |
12/31/2025 | 318,520 | -19,774 | -115,105 | -4,240 | 8 |
12/31/2024 | 234,331 | -39,542 | -193,076 | -11,000 | 7 |
3/31/2024 | 371,179 | 22,868 | -47,047 | 71,302 | N/A |
12/31/2023 | 369,506 | 22,318 | -20,949 | 29,346 | N/A |
9/30/2023 | 419,202 | 45,890 | -32,868 | 11,613 | N/A |
6/30/2023 | 278,429 | 18,276 | -162,430 | -123,743 | N/A |
3/31/2023 | 390,231 | 80,378 | -107,916 | -47,766 | N/A |
12/31/2022 | 456,726 | 122,452 | -201,448 | -124,958 | N/A |
12/31/2021 | 929,001 | 355,139 | 492,124 | 536,594 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A302440's earnings are forecast to decline over the next 3 years (-9.4% per year).
Earnings vs Market: A302440's earnings are forecast to decline over the next 3 years (-9.4% per year).
High Growth Earnings: A302440's earnings are forecast to decline over the next 3 years.
Revenue vs Market: A302440's revenue is expected to decline over the next 3 years (-3.5% per year).
High Growth Revenue: A302440's revenue is forecast to decline over the next 3 years (-3.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A302440 is forecast to be unprofitable in 3 years.